April 26, 2024
Deals
Alpha Holdings becomes largest shareholder of Viral Genes
[THE INVESTOR] Alpha Holdings announced on Oct. 13 that it has acquire additional stake in the US-based immunity anti-cancer medicine firm Viral Gene.
Including the stake held by its subsidiary Alpha Biolabs, Alpha Holding’s is now the US-based company’s largest shareholder with 37.64 percent stake.
Alpha Holdings acquired Viral Gene shares held by TJU Asset Management and Penn Life Science, which each acquired 1.66 percent of its shares.
Viral Gene is currently developing a treatment for colorectal cancer, and plans to begin phase 2 clinical trials within the year.
By Choi He-suk (cheesuk@heraldcorp.com)
Including the stake held by its subsidiary Alpha Biolabs, Alpha Holding’s is now the US-based company’s largest shareholder with 37.64 percent stake.
Alpha Holdings acquired Viral Gene shares held by TJU Asset Management and Penn Life Science, which each acquired 1.66 percent of its shares.
Viral Gene is currently developing a treatment for colorectal cancer, and plans to begin phase 2 clinical trials within the year.
By Choi He-suk (cheesuk@heraldcorp.com)
